Aruz Mesci

1.3k total citations
45 papers, 969 citations indexed

About

Aruz Mesci is a scholar working on Pulmonary and Respiratory Medicine, Immunology and Oncology. According to data from OpenAlex, Aruz Mesci has authored 45 papers receiving a total of 969 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 14 papers in Immunology and 13 papers in Oncology. Recurrent topics in Aruz Mesci's work include Immune Cell Function and Interaction (12 papers), Advanced Radiotherapy Techniques (9 papers) and T-cell and B-cell Immunology (7 papers). Aruz Mesci is often cited by papers focused on Immune Cell Function and Interaction (12 papers), Advanced Radiotherapy Techniques (9 papers) and T-cell and B-cell Immunology (7 papers). Aruz Mesci collaborates with scholars based in Canada, United States and United Kingdom. Aruz Mesci's co-authors include James R. Carlyle, Peter Chen, Andrew P. Makrigiannis, Jason H. Fine, Lee‐Hwa Tai, Simon Bélanger, Stanley K. Liu, Belma Ljutic, David Allan and Samira Taeb and has published in prestigious journals such as Cell, Journal of Clinical Oncology and Immunity.

In The Last Decade

Aruz Mesci

35 papers receiving 953 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aruz Mesci Canada 17 505 298 189 186 127 45 969
Tomoki Yamano Japan 18 289 0.6× 364 1.2× 91 0.5× 540 2.9× 74 0.6× 54 972
Koji Yamanoi Japan 12 362 0.7× 290 1.0× 228 1.2× 464 2.5× 65 0.5× 72 946
Yanina Jansen Belgium 15 192 0.4× 345 1.2× 221 1.2× 595 3.2× 88 0.7× 48 887
Alexander Puhl Germany 9 192 0.4× 377 1.3× 205 1.1× 346 1.9× 39 0.3× 17 924
Ariella Sasson United States 9 208 0.4× 267 0.9× 210 1.1× 632 3.4× 213 1.7× 16 967
David Heinz United States 15 309 0.6× 266 0.9× 69 0.4× 409 2.2× 286 2.3× 20 973
Yien Ning Sophia Wong United Kingdom 8 325 0.6× 387 1.3× 284 1.5× 687 3.7× 103 0.8× 17 1.1k
Jianqiong Zhu United States 16 135 0.3× 402 1.3× 129 0.7× 316 1.7× 80 0.6× 35 935
Zipei Feng United States 14 516 1.0× 276 0.9× 93 0.5× 692 3.7× 57 0.4× 36 1.0k

Countries citing papers authored by Aruz Mesci

Since Specialization
Citations

This map shows the geographic impact of Aruz Mesci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aruz Mesci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aruz Mesci more than expected).

Fields of papers citing papers by Aruz Mesci

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aruz Mesci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aruz Mesci. The network helps show where Aruz Mesci may publish in the future.

Co-authorship network of co-authors of Aruz Mesci

This figure shows the co-authorship network connecting the top 25 collaborators of Aruz Mesci. A scholar is included among the top collaborators of Aruz Mesci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aruz Mesci. Aruz Mesci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barry, Aisling, Xiang Y. Ye, Peter Chung, et al.. (2025). The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: A site-specific analysis of the prospective, phase II RADIANT trial. Radiotherapy and Oncology. 210. 111041–111041.
2.
Li, Winnie, et al.. (2025). Feasibility of Therapist‐Driven MR ‐Guided Adaptive Radiotherapy for Oligometastatic Disease: Geometric Accuracy and Dosimetric Impact. Journal of Medical Imaging and Radiation Oncology. 69(8). 777–786.
3.
Dawson, Laura A., et al.. (2024). Do We Have a Winner? Advocating for SBRT in HCC Management. Clinical and Translational Radiation Oncology. 45. 100740–100740. 7 indexed citations
4.
Cleary, Sean P., Laura A. Dawson, Elena Elimova, et al.. (2024). Vascular Resection for Pancreas Cancer – 10-year Experience from a Single High Volume-center. Annals of Surgery. 1 indexed citations
5.
Baskurt, Zeynep, Carly C. Barron, Xin Wang, et al.. (2024). Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes. Journal of Neuro-Oncology. 167(1). 111–122. 5 indexed citations
6.
Velec, Michael, Aisling Barry, Michael Yan, et al.. (2024). Development and validation of an MR-driven dose-of-the-day procedure for online adaptive radiotherapy in upper gastrointestinal cancer patients. Physics in Medicine and Biology. 69(16). 165009–165009.
7.
Tsakiridis, Evangelia E., Elham Ahmadi, Jianhan Wu, et al.. (2023). Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α. Molecular Oncology. 17(11). 2235–2256. 17 indexed citations
8.
Tsakiridis, Evangelia E., Elham Ahmadi, Jianhan Wu, et al.. (2023). The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Communications Biology. 6(1). 919–919. 31 indexed citations
9.
Mirshahvalad, Seyed Ali, Aruz Mesci, Andrés Kohan, et al.. (2023). [18F]-FDG PET in anal canal cancer: a systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging. 51(1). 258–277. 8 indexed citations
10.
11.
Tsakiridis, Evangelia E., Lindsay A. Broadfield, Katarina Marcinko, et al.. (2021). Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses. Translational Oncology. 14(11). 101209–101209. 13 indexed citations
12.
Wang, Hanzhi, Lucas C. Mendez, Gerard Morton, et al.. (2020). Immune cell profiling in Gleason 9 prostate cancer patients treated with brachytherapy versus external beam radiotherapy: An exploratory study. Radiotherapy and Oncology. 155. 80–85. 7 indexed citations
13.
Mesci, Aruz, Fabrice Lucien, Xiaoyong Huang, et al.. (2019). RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer. Journal of Translational Medicine. 17(1). 125–125. 18 indexed citations
14.
Vaněk, Ondřej, Jan Bláha, Daniel Kavan, et al.. (2019). Production of recombinant soluble dimeric C-type lectin-like receptors of rat natural killer cells. Scientific Reports. 9(1). 17836–17836. 5 indexed citations
15.
Mesci, Aruz, Stanley K. Liu, & D. Andrew Loblaw. (2018). Spurious elevation of Prostate‐specific antigen associated with shingles in a prostate cancer patient undergoing active surveillance. Clinical Case Reports. 6(12). 2338–2340. 4 indexed citations
16.
Huang, Xiaoyong, Samira Taeb, Sahar Jahangiri, et al.. (2013). miRNA-95 Mediates Radioresistance in Tumors by Targeting the Sphingolipid Phosphatase SGPP1. Cancer Research. 73(23). 6972–6986. 125 indexed citations
17.
Fine, Jason H., Peter Chen, Aruz Mesci, et al.. (2010). Chemotherapy-Induced Genotoxic Stress Promotes Sensitivity to Natural Killer Cell Cytotoxicity by Enabling Missing-Self Recognition. Cancer Research. 70(18). 7102–7113. 85 indexed citations
18.
Carlyle, James R., Aruz Mesci, Jason H. Fine, et al.. (2008). Evolution of the Ly49 and Nkrp1 recognition systems. Seminars in Immunology. 20(6). 321–330. 86 indexed citations
19.
Voigt, Sebastian, et al.. (2007). Cytomegalovirus Evasion of Innate Immunity by Subversion of the NKR-P1B:Clr-b Missing-Self Axis. Immunity. 26(5). 617–627. 82 indexed citations
20.
Carlyle, James R., Aruz Mesci, Belma Ljutic, et al.. (2006). Molecular and Genetic Basis for Strain-Dependent NK1.1 Alloreactivity of Mouse NK Cells. The Journal of Immunology. 176(12). 7511–7524. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomoki Yamano Breakdown of academic impact, for papers by Koji Yamanoi Breakdown of academic impact, for papers by Yanina Jansen Breakdown of academic impact, for papers by Alexander Puhl Breakdown of academic impact, for papers by Ariella Sasson Breakdown of academic impact, for papers by David Heinz Breakdown of academic impact, for papers by Yien Ning Sophia Wong Breakdown of academic impact, for papers by Jianqiong Zhu Breakdown of academic impact, for papers by Zipei Feng
Rankless by CCL
2026